Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)

NCT01143246 is registered in ClinicalTrials.gov with Mallinckrodt as lead sponsor.

NCT NCT01143246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01143246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Randomized, Placebo-controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Lucassin® (Terlipressin) (The REVERSE Study)
Lead sponsor
Mallinckrodt
Phase
Phase 3
Overall status
Completed
Start date
October 11, 2010
Completion date
May 10, 2013
Enrollment
196 (actual)
Sites
73

Conditions

As the registry lists them; a condition with its own page is linked.

hepatorenal syndrome